New drug combo shows promise for Hard-to-Treat gynecological cancers

NCT ID NCT05512208

Recruiting now Disease control Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of two drugs, VS-6766 and defactinib, can shrink or control certain gynecological cancers that have come back. It includes women with endometrioid, ovarian, or cervical cancers that have specific gene changes (RAS, BRAF, or NF1). The goal is to see if the treatment is effective and safe, with participants taking the drugs indefinitely as long as they benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer endometrioid adenocarcinoma female reproductive organ cancer mucinous ovarian cancer ovarian serous adenocarcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER ENDOMETRIOID CANCER HIGH GRADE SEROUS OVARIAN CANCER MUCINOUS OVARIAN CANCER SOLID TUMOR

Contacts and locations

Locations

AdventHealth
RECRUITING

Orlando, Florida, 32804, United States
Louisiana State University Medical Center New Orleans
RECRUITING

New Orleans, Louisiana, 70112, United States
Stephenson Cancer Center
RECRUITING

Oklahoma City, Oklahoma, 73117, United States
University of New Mexico Comprehensive Cancer Center
RECRUITING

Albuquerque, New Mexico, 87131, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.